Logo image of LFAC

LF CAPITAL ACQUISITION -CLA (LFAC) Stock Fundamental Analysis

NASDAQ:LFAC - Nasdaq - US50202D1028 - Common Stock - Currency: USD

10.84  -0.02 (-0.18%)

Fundamental Rating

1

Overall LFAC gets a fundamental rating of 1 out of 10. We evaluated LFAC against 0 industry peers in the Unkown industry. LFAC has a bad profitability rating. Also its financial health evaluation is rather negative. LFAC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LFAC had positive earnings in the past year.
LFAC had a negative operating cash flow in the past year.
In multiple years LFAC reported negative net income over the last 5 years.
LFAC had a negative operating cash flow in each of the past 5 years.
LFAC Yearly Net Income VS EBIT VS OCF VS FCFLFAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 0 1M -1M

1.2 Ratios

Industry RankSector Rank
ROA 2.64%
ROE 6.9%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LFAC Yearly ROA, ROE, ROICLFAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 0 50 -50 100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LFAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LFAC Yearly Profit, Operating, Gross MarginsLFAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022

More info and screens

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, LFAC has about the same amount of shares outstanding.
LFAC has a worse debt/assets ratio than last year.
LFAC Yearly Shares OutstandingLFAC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2021 2022 10M 20M 30M
LFAC Yearly Total Debt VS Total AssetsLFAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

LFAC has an Altman-Z score of 0.76. This is a bad value and indicates that LFAC is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of 0.05 indicates that LFAC is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 0.76
ROIC/WACCN/A
WACCN/A
LFAC Yearly LT Debt VS Equity VS FCFLFAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2021 2022 0 50M 100M 150M 200M 250M

2.3 Liquidity

LFAC has a Current Ratio of 0.06. This is a bad value and indicates that LFAC is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.06 indicates that LFAC may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
LFAC Yearly Current Assets VS Current LiabilitesLFAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2021 2022 200K 400K 600K 800K

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 579.65% over the past year.
Measured over the past years, LFAC shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -12.41% on average per year.
EPS 1Y (TTM)579.65%
EPS 3Y-12.41%
EPS 5YN/A
EPS Q2Q%-27.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LFAC Yearly Revenue VS EstimatesLFAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022
LFAC Yearly EPS VS EstimatesLFAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LFAC is valuated quite expensively with a Price/Earnings ratio of 108.40.
LFAC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 29.62.
Industry RankSector Rank
PE 108.4
Fwd PE N/A
LFAC Price Earnings VS Forward Price EarningsLFAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LFAC Per share dataLFAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LFAC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LF CAPITAL ACQUISITION -CLA

NASDAQ:LFAC (10/2/2023, 8:00:04 PM)

10.84

-0.02 (-0.18%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-08 2022-11-08
Earnings (Next)03-08 2023-03-08
Inst Owners3.94%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap131.92M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 108.4
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.84
P/tB 2.84
EV/EBITDA N/A
EPS(TTM)0.1
EY0.92%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS3.82
TBVpS3.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.64%
ROE 6.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z 0.76
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)579.65%
EPS 3Y-12.41%
EPS 5YN/A
EPS Q2Q%-27.77%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-158.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-106.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.4%
OCF growth 3YN/A
OCF growth 5YN/A